NEXT
Sign in to follow

The Legal Intelligencer

Guidance Regarding a Standing Requirement for IPR Appeals in 2 Recent Pharma Cases

Thanks to recent decisions by the U.S. Court of Appeals for the Federal Circuit (CAFC), we have clarity that both requirements must be met to appeal an adverse final written decision issued during that IPR, and we also have some guidance as to how these requirements will be determined in such cases.
8 minute read

New York Law Journal

Alexa, Will I Be Able to Patent My Artificial Intelligence Technology This Year?

Considering the advances in AI technology and intellectual property law, how do these recent developments shape the outlook of AI patentability?
8 minute read

New York Law Journal

The Uphill Battle: Challenging Bio-Pharma in IPRs

Since the Hatch-Waxman Act has been in effect, there has been an increase in the number of challenges to patents covering chemical compounds. With the advent of inter partes reviews, the expectation was that there would be an uptick in compound claims being found obvious due to the expertise of the Patent Trial and Appeal Board. That has not been the case. Instead, as outlined here, the exact opposite has happened.
8 minute read

Litigation Daily

Shout-Out: $26M Win for Clare Locke in Defamation Suit

Husband and wife litigators Tom Clare and Libby Locke—founders of Kirkland & Ellis spin-off boutique Clare Locke—led a team in winning a $26 million defamation verdict against Puma Biotechnology and its CEO.
2 minute read

New York Law Journal

How to Win Work From NY's Thriving Startup Sector: Three Proven Strategies

The firms that experiment with the strategies outlined in this article will be among those most likely to succeed.
6 minute read

The Legal Intelligencer

Advising Life Sciences Clients on Private Equity

If you represent early stage life sciences companies entering the capital markets, you may be asked to opine on the financing and business issues they face. Below is a general overview of some of the issues that you will need to understand to provide solid advice.
9 minute read

Litigation Daily

Daily Dicta: Wilmer, Latham Lawyers Swatted in Red-Hot Discovery Fight over World's Best-Selling Drug

A fed-up magistrate judge in Delaware ordered pharma giant AbbVie to turn over requested discovery materials to Boehringer Ingelheim in a patent fight over Humira, the world's best-selling drug.
7 minute read

Litigation Daily

Litigators of the Week: Latham's Lethal IP Litigators Kill Patent Challenge to $2B-a-Year Drug

Latham & Watkins global IP co-chair Michael Morin and partner David Frazier delivered a save worth billions to clients Janssen Biotech Inc. and Genmab A/S.
11 minute read

National Law Journal

Latham Blocks Patent Attack on $2 Billion-a-Year Blood Cancer Drug

MorphoSys and Kirkland & Ellis had accused a Janssen Pharmaceuticals biologic of infringing, but Judge Leonard Stark ruled MorphoSys' patents invalid for lack of enablement.
3 minute read

Litigation Daily

Latham Defeats Patent Attack on $2 Billion-a-Year Blood Cancer Drug

MorphoSys and Kirkland & Ellis had accused a Janssen Pharmaceuticals biologic of infringing, but Judge Leonard Stark ruled MorphoSys' patents invalid for lack of enablement.
3 minute read

More from ALM

More from ALM

Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

Resources

  • Aligning Client Needs with Lawyer Growth and Profitability

    Brought to you by BigHand

    Download Now

  • Technology to Make E-Discovery Smarter, Not Harder

    Brought to you by Nuix

    Download Now

  • Does Generative AI Have the Power to Transform Legal Services?

    Brought to you by HaystackID

    Download Now

  • How This Personal Injury Firm Reduced Client Intake Time by 80%

    Brought to you by PracticePanther

    Download Now